Ipsen Biopharmaceuticals Canada Inc.

Jan 07, 2020

Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection)

Oct 15, 2019

Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma

Oct 16, 2018

Health Canada approves XERMELO(TM) (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)

Sep 19, 2018

Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma

Feb 13, 2018

Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Sep 05, 2017

Innovative Medicines Canada welcomes Akcea Therapeutics Canada and Ipsen Biopharmaceuticals Canada as its newest members

Sep 05, 2017

Ipsen Biopharmaceuticals Canada Names Paul Reider Country Manager and Joins Innovative Medicines Canada to Drive Development and Delivery of Key Therapies